SAN DIEGO and SUZHOU, China – Adagene Inc. (NASDAQ: ADAG), a biotechnology firm with a market capitalization of $85 million focused on antibody-based cancer therapies, has revealed encouraging clinical data from a trial involving its novel drug, ADG126, for treating microsatellite stable colorectal cancer (MSS CRC). The announcement came following a presentation at the ASCO Gastrointestinal Cancers Symposium in San Francisco. According to…